Myocarditis after BNT162b2 Vaccination in Israeli Adolescents | NEJM

We previously reported that the incidence of myocarditis in Israel after receipt of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) against coronavirus disease 2019 (Covid-19) was highest among males between the ages of 16 and 29 years (10.7 cases per 100,000 persons).1 BNT162b2 vaccination has since been approved for adolescents between the ages of 12 and 15 years, and initial evidence from this age group in Israel suggests a similar incidence and mild course of myocarditis, although follow-up was limited to 30 days.2 A study from Hong Kong showed an incidence of 28.7 cases per 100,000 persons, but cases were not adjudicated beyond the discharge diagnosis code of the International Classification of Diseases, Ninth Revision (ICD-9).3 Our aim was to provide further evidence regarding the incidence of myocarditis after vaccination among adolescents and data regarding follow-up of 6 months or more.

Source: Myocarditis after BNT162b2 Vaccination in Israeli Adolescents | NEJM

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: